Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Single Rising Oral Doses of BI 690517 in Healthy Males
NCT02891148Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of vicadrostat in chronic kidney disease (CKD), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of subjects with adverse reactions up to 14 days. Started Sep 2016; status: completed.
02
Drugs
vicadrostat
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT02891148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02891148.